lacutamab
innate
['lacuta', 'ctcl,(-ctclaboratory)', 'innate pharma', 'innatepharma']
today innate presented data from a preliminary analysis of the tellomak phase 2 trial of lacutamab at #ash22, which demonstrated clinical activity and a favorable safety profile in patients with #sezarysyndrome. learn more: 
#Biotech #Immunotherapy #ImmunoOncology #Cancer #Inflammation #Antibody #Checkpoints